AMRX · Amneal Pharmaceuticals, Inc. · Insider Trading

On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust.

The option is vested and currently exercisable.

Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee.

Represents a gift to trust for the benefit of certain family members whereby reporting person does not serve as trustee.

Represents a charitable donation of common stock to a donor advised fund.

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.26 to $17.88 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.40 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.67 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.65 to $17.73 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

The price included in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.07 to $17.31 per share, inclusive. The Reporting Person undertakes to provide to Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnote.

On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition.

On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition.

On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the "Purchase Agreement"), by and among the Issuer, Kashiv BioSciences, LLC ("Kashiv"), KB Seller Representative, LLC and the equityholders of Kashiv named therein (the "Sellers"), a subsidiary of the Issuer purchased (the "Acquisition") from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock ("Class A Common Stock"). Pursuant to the terms of the Purchase Agreement, a limited liability company managed by the Reporting Person received 12,763,469 shares of Class A Common Stock in the Acquisition.

On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 283,632 shares of Class A Common Stock in the Acquisition.

The price included in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.75 to $13.27 per share, inclusive. The Reporting Person undertakes to provide Amneal Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On May 6, 2025, the reporting person was granted 48,747 restricted stock units vesting on May 7, 2026.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On May 6, 2025, the reporting person was granted 34,819 restricted stock units vesting on May 7, 2026.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant.

Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On March 4, 2024, the reporting person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

On March 4, 2024, the reporting person was granted 152,778 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.